These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 2544323)

  • 1. Intramuscular administration of iron during long-term chelation therapy with 2,3-dimercaptosuccinic acid in a man with severe lead poisoning.
    Haust HL; Inwood M; Spence JD; Poon HC; Peter F
    Clin Biochem; 1989 Jun; 22(3):189-96. PubMed ID: 2544323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dimercaptosuccinic acid (succimer; DMSA) in inorganic lead poisoning.
    Bradberry S; Vale A
    Clin Toxicol (Phila); 2009 Aug; 47(7):617-31. PubMed ID: 19663612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mobilization of lead over the course of DMSA chelation therapy and long-term efficacy.
    Cory-Slechta DA
    J Pharmacol Exp Ther; 1988 Jul; 246(1):84-91. PubMed ID: 2839672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beneficial effect of combined administration of some naturally occurring antioxidants (vitamins) and thiol chelators in the treatment of chronic lead intoxication.
    Flora SJ; Pande M; Mehta A
    Chem Biol Interact; 2003 Jun; 145(3):267-80. PubMed ID: 12732454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2,3-Dimercaptosuccinic acid as an antidote for lead intoxication.
    Graziano JH; Siris ES; LoIacono N; Silverberg SJ; Turgeon L
    Clin Pharmacol Ther; 1985 Apr; 37(4):431-8. PubMed ID: 2983924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of meso-2,3-dimercaptosuccinic acid on urinary lead excretion in exposed men.
    Torres-Alanís O; Garza-Ocañas L; Piñeyro-López A
    Hum Exp Toxicol; 2002 Nov; 21(11):573-7. PubMed ID: 12507251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlled study of meso-2,3-dimercaptosuccinic acid for the management of childhood lead intoxication.
    Graziano JH; Lolacono NJ; Moulton T; Mitchell ME; Slavkovich V; Zarate C
    J Pediatr; 1992 Jan; 120(1):133-9. PubMed ID: 1309865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of oral dimercaptosuccinic acid (succimer) in adult patients with inorganic lead poisoning.
    Bradberry S; Sheehan T; Vale A
    QJM; 2009 Oct; 102(10):721-32. PubMed ID: 19700440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined chelation therapy in reducing tissue lead concentrations in suckling rats.
    Kostial K; Blanusa M; Piasek M; Restek-Samarzija N; Jones MM; Singh PK
    J Appl Toxicol; 1999; 19(3):143-7. PubMed ID: 10362263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of succimer chelation for reducing brain Pb levels in a rodent model.
    Smith D; Bayer L; Strupp BJ
    Environ Res; 1998 Aug; 78(2):168-76. PubMed ID: 9719621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chelated lead in relation to lead in bone and ALAD genotype.
    Gerhardsson L; Börjesson J; Mattsson S; Schütz A; Skerfving S
    Environ Res; 1999 May; 80(4):389-98. PubMed ID: 10330313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of sodium calcium edetate (edetate calcium disodium) and succimer (DMSA) in the treatment of inorganic lead poisoning.
    Bradberry S; Vale A
    Clin Toxicol (Phila); 2009 Nov; 47(9):841-58. PubMed ID: 19852620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the potential role of chelation therapy in treatment of low to moderate lead exposures.
    Chisolm JJ
    Environ Health Perspect; 1990 Nov; 89():67-74. PubMed ID: 1965166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of chelate treatments on kidney, bone and brain lead levels of lead-intoxicated mice.
    Jones MM; Basinger MA; Gale GR; Atkins LM; Smith AB; Stone A
    Toxicology; 1994 Apr; 89(2):91-100. PubMed ID: 8197593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling the effect of succimer (DMSA; dimercaptosuccinic acid) chelation therapy in patients poisoned by lead.
    van Eijkeren JC; Olie JD; Bradberry SM; Vale JA; de Vries I; Clewell HJ; Meulenbelt J; Hunault CC
    Clin Toxicol (Phila); 2017 Feb; 55(2):133-141. PubMed ID: 27919185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Description of 3,180 courses of chelation with dimercaptosuccinic acid in children ≤ 5 y with severe lead poisoning in Zamfara, Northern Nigeria: a retrospective analysis of programme data.
    Thurtle N; Greig J; Cooney L; Amitai Y; Ariti C; Brown MJ; Kosnett MJ; Moussally K; Sani-Gwarzo N; Akpan H; Shanks L; Dargan PI
    PLoS Med; 2014 Oct; 11(10):e1001739. PubMed ID: 25291378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impacts of lead exposure and chelation therapy on bone metabolism during different developmental stages of rats.
    Zhang Y; Zhou L; Li S; Liu J; Sun S; Ji X; Yan C; Xu J
    Ecotoxicol Environ Saf; 2019 Nov; 183():109441. PubMed ID: 31404725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of succimer chelation for reducing brain lead in a primate model of human lead exposure.
    Cremin JD; Luck ML; Laughlin NK; Smith DR
    Toxicol Appl Pharmacol; 1999 Dec; 161(3):283-93. PubMed ID: 10620486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disappearance of heme metabolites following chelation therapy with meso 2,3-dimercaptosuccinic acid (DMSA).
    Tutunji MF; al-Mahasneh QM
    J Toxicol Clin Toxicol; 1994; 32(3):267-76. PubMed ID: 8007034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Succimer treatment during ongoing lead exposure reduces tissue lead in suckling rats.
    Varnai VM; Piasek M; Blanusa M; Sarić MM; Kostial K
    J Appl Toxicol; 2001; 21(5):415-6. PubMed ID: 11746184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.